MX362591B - Uso de antagonistas de il-17. - Google Patents
Uso de antagonistas de il-17.Info
- Publication number
- MX362591B MX362591B MX2013005060A MX2013005060A MX362591B MX 362591 B MX362591 B MX 362591B MX 2013005060 A MX2013005060 A MX 2013005060A MX 2013005060 A MX2013005060 A MX 2013005060A MX 362591 B MX362591 B MX 362591B
- Authority
- MX
- Mexico
- Prior art keywords
- rheumatoid arthritis
- antagonists
- methods
- treating rheumatoid
- antibody
- Prior art date
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000004554 Interleukin-17 Receptors Human genes 0.000 abstract 1
- 108010017525 Interleukin-17 Receptors Proteins 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229960004540 secukinumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a un artículo para IL-17 para usarse en el tratamiento de un paciente con espondilitis anquilosantes (AS), en donde el anticuerpo está adaptado para ser administrable a través de: a) cinco dosis subcutáneas de aproximadamente 150 mg a aproximadamente 300 mg del anticuerpo para IL-17, cada una de las cinco dosis adaptada para ser administrable semanalmente; y b) en adelante, una dosis subcutánea de aproximadamente 150 mg a aproximadamente 300 mg del anticuerpo para IL-17 cada 4 semanas, en donde el anticuerpo para IL-17 tiene una KD de aproximadamente aproximadamente 100 a 200 pM, medida por Biacore, y en donde dicho anticuerpo para IL-17 comprende: 1) un dominio VH de inmunoglobulina que comprende la secuencia de aminoácidos SEQ ID NO: 8 y un dominio VL de inmunoglobulina que comprende la secuencia de aminoácidos SEQ ID NO: 10; ii) un dominio VH de inmunoglobulina que comprende las regiones hipervariables como las SEQ ID NO: 1, SEQ ID NO; 2, y SEQ ID NO: 3, y un dominio VL de inmunoglobulina que comprende las regiones hipervarialbes como las SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6; o iii) un domino VH de inmunoglobulina que comprende las regiones hipervariables como las SEQ ID NO: 11, SEQ ID NO: 12, y SEQ ID NO: 13, y un dominio VL de inmunoglobulina que comprende las regiones hIpervariables las SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41053310P | 2010-11-05 | 2010-11-05 | |
| PCT/EP2011/069476 WO2012059598A2 (en) | 2010-11-05 | 2011-11-04 | Methods of treating rheumatoid arthritis using il-17 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005060A MX2013005060A (es) | 2013-06-28 |
| MX362591B true MX362591B (es) | 2019-01-25 |
Family
ID=44906168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005060A MX362591B (es) | 2010-11-05 | 2011-11-04 | Uso de antagonistas de il-17. |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US9744234B2 (es) |
| EP (6) | EP3912640A1 (es) |
| JP (7) | JP2014503482A (es) |
| KR (5) | KR20160067984A (es) |
| CN (2) | CN104800844A (es) |
| AU (1) | AU2011325134B2 (es) |
| BR (1) | BR112013011176A2 (es) |
| CA (2) | CA3116725C (es) |
| CL (1) | CL2013001213A1 (es) |
| CY (1) | CY1121802T1 (es) |
| DE (1) | DE20187001T1 (es) |
| DK (1) | DK3111954T3 (es) |
| ES (2) | ES2733712T3 (es) |
| HR (1) | HRP20191162T1 (es) |
| HU (1) | HUE044038T2 (es) |
| IL (4) | IL311014A (es) |
| LT (1) | LT3111954T (es) |
| MA (1) | MA34647B1 (es) |
| MX (1) | MX362591B (es) |
| PH (1) | PH12013500890A1 (es) |
| PL (1) | PL3111954T3 (es) |
| PT (1) | PT3111954T (es) |
| RU (1) | RU2582937C2 (es) |
| SG (2) | SG10201505624VA (es) |
| SI (1) | SI3111954T1 (es) |
| TR (1) | TR201909531T4 (es) |
| TW (3) | TWI604851B (es) |
| WO (1) | WO2012059598A2 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ603570A (en) | 2010-05-20 | 2014-12-24 | Ablynx Nv | Biological materials related to her3 |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| RS60828B1 (sr) | 2011-10-11 | 2020-10-30 | Viela Bio Inc | Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| US9688769B2 (en) | 2013-10-22 | 2017-06-27 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
| KR20160113268A (ko) * | 2014-01-28 | 2016-09-28 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 이기능 융합단백질,이의 제조방법 및 용도 |
| CN106456756B (zh) | 2014-05-13 | 2021-04-23 | 免疫医疗有限公司 | 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体 |
| US11548940B2 (en) * | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CN107072955B (zh) | 2014-05-15 | 2021-06-18 | 拉尼医疗有限公司 | 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法 |
| FR3021976B1 (fr) * | 2014-06-06 | 2018-11-02 | Hospices Civils De Lyon | Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu |
| US20160002326A1 (en) * | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
| NL2013007B1 (en) * | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| MX2017003216A (es) * | 2014-09-10 | 2017-05-23 | Novartis Ag | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. |
| WO2016064817A1 (en) * | 2014-10-22 | 2016-04-28 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CA2978449A1 (en) | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| AU2016342578A1 (en) * | 2015-10-19 | 2018-03-29 | Novartis Ag | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (IL-17) antagonists |
| US20190183991A1 (en) * | 2016-08-23 | 2019-06-20 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency |
| US20210179702A1 (en) * | 2017-11-02 | 2021-06-17 | Novartis Ag | Method of treating tendinopathy using interleukin-17 (il-17) |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| EP3790576A1 (en) * | 2018-05-09 | 2021-03-17 | Novartis Ag | Use of canakinumab |
| MX2021003514A (es) * | 2018-09-26 | 2021-05-27 | Viela Bio Inc | Antagonista del ligando del grupo de diferenciacion 40 (cd40l) y usos del mismo. |
| CN118453606A (zh) * | 2019-01-22 | 2024-08-09 | 豪夫迈·罗氏有限公司 | 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| BR112022002150A2 (pt) * | 2019-08-05 | 2022-06-07 | Evelo Biosciences Inc | Composições e métodos para tratar psoríase e dermatite atópica com o uso de prevotella histicola |
| IL292926A (en) | 2019-11-19 | 2022-07-01 | Novartis Ag | Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists |
| CN112915201B (zh) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| WO2021146850A1 (en) * | 2020-01-20 | 2021-07-29 | Tsinghua University | A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4 |
| US20240101659A1 (en) * | 2020-11-25 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Stable therapeutic protein formulation and methods of making the same |
| TW202241505A (zh) * | 2021-01-04 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| KR102339377B1 (ko) * | 2021-03-29 | 2021-12-13 | 김지혜 | 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치 |
| WO2022271544A1 (en) * | 2021-06-21 | 2022-12-29 | Bristol-Myers Squibb Company | Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products |
| CN114306594A (zh) * | 2021-12-21 | 2022-04-12 | 华中科技大学同济医学院附属协和医院 | 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用 |
| WO2024156841A1 (en) | 2023-01-27 | 2024-08-02 | Fresenius Kabi Deutschland Gmbh | Biopharmaceutical composition |
| EP4406553A1 (en) | 2023-01-27 | 2024-07-31 | Fresenius Kabi Deutschland GmbH | Stable secukinumab biopharmaceutical composition |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| US5250442A (en) * | 1993-04-08 | 1993-10-05 | Orestes Cabezas | Method of treating rheumatoid arthritis using tetracycline |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP2261335B1 (en) | 1998-11-27 | 2017-06-14 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralisation |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| JP2005508992A (ja) | 2001-11-09 | 2005-04-07 | セントカー・インコーポレーテツド | 凍結乾燥されたモノクローナル抗体組成物 |
| WO2003073991A2 (en) | 2002-03-01 | 2003-09-12 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US6974701B2 (en) | 2003-03-21 | 2005-12-13 | Hemovations, Llc | Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same |
| AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JP3936365B2 (ja) | 2004-09-14 | 2007-06-27 | ソニーケミカル＆インフォメーションデバイス株式会社 | 機能素子実装モジュール及びその製造方法 |
| EP1868646A2 (en) * | 2005-03-08 | 2007-12-26 | Pharmacia & Upjohn Company LLC | Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US20090221568A1 (en) | 2005-11-04 | 2009-09-03 | Jared Shaw | Synthesis of Inhibitors of FtsZ |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| WO2007117749A2 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies fpr treating cancer |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| BRPI0714893A2 (pt) | 2006-09-05 | 2013-05-28 | Medarex Inc | anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo |
| JPWO2008029908A1 (ja) | 2006-09-07 | 2010-01-21 | 協和発酵キリン株式会社 | 抗体を含有する安定な凍結乾燥医薬製剤 |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| CN101541833B (zh) * | 2006-10-02 | 2014-01-29 | 麒麟-安姆根有限公司 | Il-17受体a抗原结合蛋白质 |
| EP2094731A2 (en) | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
| EP2097450A2 (en) | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008092894A1 (en) | 2007-02-02 | 2008-08-07 | Novartis Ag | Modulators of sclerostin binding partners for treating bone-related disorders |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CA2681743A1 (en) | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
| EP2068923A4 (en) * | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES |
| CN101932935A (zh) | 2007-06-20 | 2010-12-29 | 先灵公司 | 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记 |
| US7720605B2 (en) | 2007-06-22 | 2010-05-18 | Weyerhaeuser Nr Company | Identifying vegetation attributes from LiDAR data |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| EA201070740A1 (ru) | 2007-12-14 | 2010-12-30 | Эмджен Инк. | Способ лечения перелома кости антителами против склеростина |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009268585C1 (en) | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| AU2009296299A1 (en) | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human IL 17 and uses thereof |
| EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| FR2938547B1 (fr) | 2008-11-14 | 2012-11-16 | Total Raffinage Marketing | Liant synthetique clair |
| WO2010065491A2 (en) | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| JP5836807B2 (ja) | 2009-03-05 | 2015-12-24 | アッヴィ・インコーポレイテッド | Ｉｌ−１７結合タンパク質 |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| AR084234A1 (es) | 2010-12-13 | 2013-05-02 | Novartis Ag | Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) |
-
2011
- 2011-11-04 MX MX2013005060A patent/MX362591B/es active IP Right Grant
- 2011-11-04 CN CN201510199026.8A patent/CN104800844A/zh active Pending
- 2011-11-04 HU HUE16163440A patent/HUE044038T2/hu unknown
- 2011-11-04 EP EP21180656.7A patent/EP3912640A1/en active Pending
- 2011-11-04 RU RU2013125775/15A patent/RU2582937C2/ru active
- 2011-11-04 IL IL311014A patent/IL311014A/en unknown
- 2011-11-04 TW TW100140410A patent/TWI604851B/zh active
- 2011-11-04 KR KR1020167014431A patent/KR20160067984A/ko active Search and Examination
- 2011-11-04 AU AU2011325134A patent/AU2011325134B2/en not_active Expired - Fee Related
- 2011-11-04 KR KR1020137011539A patent/KR20140008305A/ko not_active Application Discontinuation
- 2011-11-04 CN CN2011800529537A patent/CN103189074A/zh active Pending
- 2011-11-04 KR KR1020187034385A patent/KR20180129991A/ko not_active Application Discontinuation
- 2011-11-04 JP JP2013537154A patent/JP2014503482A/ja active Pending
- 2011-11-04 WO PCT/EP2011/069476 patent/WO2012059598A2/en active Application Filing
- 2011-11-04 EP EP19162707.4A patent/EP3542820A1/en not_active Withdrawn
- 2011-11-04 LT LTEP16163440.7T patent/LT3111954T/lt unknown
- 2011-11-04 PH PH1/2013/500890A patent/PH12013500890A1/en unknown
- 2011-11-04 ES ES16163440T patent/ES2733712T3/es active Active
- 2011-11-04 KR KR1020157003096A patent/KR20150020734A/ko not_active Application Discontinuation
- 2011-11-04 BR BR112013011176-3A patent/BR112013011176A2/pt not_active IP Right Cessation
- 2011-11-04 PL PL16163440T patent/PL3111954T3/pl unknown
- 2011-11-04 EP EP22180976.7A patent/EP4116325A1/en active Pending
- 2011-11-04 DE DE20187001.1T patent/DE20187001T1/de active Pending
- 2011-11-04 SG SG10201505624VA patent/SG10201505624VA/en unknown
- 2011-11-04 US US13/877,585 patent/US9744234B2/en active Active
- 2011-11-04 EP EP16163440.7A patent/EP3111954B1/en not_active Revoked
- 2011-11-04 TW TW104103341A patent/TWI616204B/zh active
- 2011-11-04 CA CA3116725A patent/CA3116725C/en active Active
- 2011-11-04 TW TW105142587A patent/TWI618543B/zh active
- 2011-11-04 CA CA2813849A patent/CA2813849C/en active Active
- 2011-11-04 SG SG2013023064A patent/SG189138A1/en unknown
- 2011-11-04 PT PT16163440T patent/PT3111954T/pt unknown
- 2011-11-04 TR TR2019/09531T patent/TR201909531T4/tr unknown
- 2011-11-04 EP EP11778903.2A patent/EP2635303A2/en not_active Withdrawn
- 2011-11-04 ES ES20187001T patent/ES2804624T1/es active Pending
- 2011-11-04 KR KR1020187004058A patent/KR20180019247A/ko active Search and Examination
- 2011-11-04 EP EP20187001.1A patent/EP3757126A1/en active Pending
- 2011-11-04 SI SI201131750T patent/SI3111954T1/sl unknown
- 2011-11-04 DK DK16163440.7T patent/DK3111954T3/da active
-
2013
- 2013-03-18 IL IL225309A patent/IL225309B/en active IP Right Grant
- 2013-05-03 CL CL2013001213A patent/CL2013001213A1/es unknown
- 2013-05-03 MA MA35873A patent/MA34647B1/fr unknown
-
2015
- 2015-11-30 JP JP2015232562A patent/JP6049843B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139469A patent/JP6250109B2/ja active Active
-
2017
- 2017-07-20 US US15/654,854 patent/US10363307B2/en active Active
- 2017-11-21 JP JP2017223669A patent/JP6515168B2/ja active Active
-
2018
- 2018-10-24 IL IL262559A patent/IL262559B/en unknown
-
2019
- 2019-04-12 JP JP2019076324A patent/JP2019142912A/ja active Pending
- 2019-06-12 US US16/439,423 patent/US20190307880A1/en not_active Abandoned
- 2019-06-26 HR HRP20191162TT patent/HRP20191162T1/hr unknown
- 2019-07-03 CY CY20191100708T patent/CY1121802T1/el unknown
-
2020
- 2020-03-19 US US16/824,613 patent/US11534491B2/en active Active
- 2020-12-18 US US17/127,758 patent/US20210128726A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,729 patent/US20210177966A1/en not_active Abandoned
- 2021-03-01 JP JP2021031383A patent/JP2021104995A/ja active Pending
- 2021-04-25 IL IL282625A patent/IL282625A/en unknown
- 2021-12-08 US US17/545,894 patent/US20220193234A1/en active Pending
-
2022
- 2022-10-21 US US18/048,797 patent/US20230293683A1/en active Pending
- 2022-12-02 US US18/061,221 patent/US20230346926A1/en active Pending
-
2023
- 2023-05-23 JP JP2023084472A patent/JP2023109910A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500890A1 (en) | Methods of treating rheumatoid arthritis using il-17 antagonists | |
| MX356279B (es) | Métodos para el tratamiento de soriasis usando antagonistas de il-17. | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| MX2021015309A (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso. | |
| MX2023000079A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales. | |
| UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| PH12012501617A1 (en) | Antagonist anti-il-7 receptor antibodies and methods | |
| EA201290254A1 (ru) | Антагонисты il-17a | |
| WO2011154139A3 (en) | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| MY175878A (en) | Anti-il-17 antibodies, a method for producing and using thereof | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| EA201170636A1 (ru) | Антагонисты толл-подобного рецептора 3 | |
| WO2012103360A3 (en) | Wnt compositions and methods of use thereof | |
| UA106529C2 (uk) | Гуманізоване антитіло до cxcr4 для лікування раку | |
| WO2012009631A8 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
| EA201171307A1 (ru) | Антагонисты толл-подобного рецептора 3 | |
| EA201390537A1 (ru) | Антигенсвязывающие белки, связывающиеся с онкостатином м (osm) | |
| EA201490623A1 (ru) | Антагонисты толл-подобного рецептора 3 для лечения метаболических и сердечно-сосудистых заболеваний | |
| IN2014DN07875A (es) | ||
| TN2013000144A1 (en) | Methods of treating rheumatoid arthuritis using il-17 antagonists | |
| TN2013000145A1 (en) | Methods of treating psoriasis using il-17 antagonists | |
| AR124605A2 (es) | Anticuerpos anti-il-36r | |
| NZ768582A (en) | Antibodies and uses thereof to detect folate receptor 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |